The National Cancer Institute (NCI) plans to procure on a sole source basis for a Biacore X100 Processing Unit along with the following components: Biacore X100 Consumable Startup Package, Biacore Computer System including CPu, monitor, and printer, Biacore X100 New User Web Based Training, Integrated and web-based methodology and evaluation support , Biacore X100 Warranty, Biacore X100 system installation with GE Healthcare Bio-Sciences Corp., 800 Centennial Avenue, P.O. Box 1327, Piscataway, NJ 08855-1327. This acquisition will be processed under FAR Part 12 Acquisition for Commercial Items and will be made pursuant to the authority in FAR 13.106-(b)(1) and 13.501-(a)(1) to use simplified procedures for commercial acquisitions. The North American Industry Classification System Code is 334516 and the business size standard is 500 employees. The following salient characteristics apply to the Biacore X100 Processing Unit, components, and technology: - The system must allow label-free protein interaction analysis based on surface plasmon resonance. - The system must support the analysis of antibody/antigen and other protein/protein interactions in a variety of assay types to determine binding specificity (including epitope mapping), binding affinity, and binding kinetics without a need for large amounts of purified protein. - The system must be able to detect association rate constants over a range of 10^3-10^7 M^-1 s^-1 and dissociation rate constants over a range of 5x10^-6 -0.5 s^-1. - The system must be automated to accept up to 15 individual sample tubes per run, allowing up to 24 hours of unattended sample analysis. - The system software must be user friendly, based on a Windows XP operating system, and networked to a 24/7 help center to address issues at any time of the day or night. - The system must allow a flow rate range from 1-100 uL/min. - The system must have a typical detection limit of 0.1 nM for >10 kDa analytes and 1 nM for <10 kDa analytes. - The system must be able to accommodate sensor chip surfaces that facilitate protein immobilization via amino, carboxyl, and thiol groups. Pre-coated sensor chip surfaces compatible with the system that allow immobilization of biotinylated analytes as well as analytes with His tags must be commercially available. JUSTIFICATION: 1. Statutory authority: Statute: 13.106-(b)(1) and 13.501(a)(1) (b) Soliciting from a single source. (1) For purchases not exceeding the simplified acquisition threshold, contracting officers may solicit from one source if the contracting officer determines that the circumstances of the contract action deem only one source reasonably available (e.g., urgency, exclusive licensing agreements, or industrial mobilization). (2) For Sole source acquisition of commercial items in excess of the simplified acquisition threshold conducted pursuant to subpart 13.5, the requirements at 13.501(a) apply. For more than 10 years, Dr. Rader has applied plasmon surface resonance for the kinetic and thermodynamic characterization of antibody/antigen interactions. Biacore instruments were the first to utilize surface plasmon resonance and clearly have remained the standard in the field with over 5,000 peer reviewed scientific publications. No other technique provides such comprehensive information in real-time and from one system. The purchase of a Biacore X100 instrument allows Dr. Rader to build on his knowledge and pass it on to his students. In addition, the Biacore X100 instrument has many advantages over any other instrument or technology offered today. Of particular importance to the Antibody Technology Section are unique features not found in any other commercially available instruments, including the detection of a very broad range of kinetic constants, sample capacity, assay flexibility, new user-friendly software, and 24/7 online help center. In addition, the Biacore X100 instrument has ten times higher sensitivity than any other available label-free technologies on the market This is not a solicitation for competitive quotations. However, if any interested party believes they can meet the above requirement, they may submit a statement of capabilities. All information furnished shall be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the NCI contracting office by 1:00 PM ET on December 3, 2007. All questions must be in writing and can be faxed (301) 402-4513 or emailed to Melissa Marino, Contract Specialist at [email protected]. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) www.ccr.gov and the Online Representations and Certifications Applications (ORCA), http://orca.bpn.gov. No collect calls will be accepted. Please reference NCI-80012-MM on all correspondence.

Bid Protests Not Available